share_log

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Truluck Joseph

Adial Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities

Adial Pharmaceuticals | 4：持股變動聲明
美股SEC公告 ·  03/28 06:10
牛牛AI助理已提取核心訊息
Joseph Truluck, the Chief Financial Officer of Adial Pharmaceuticals, Inc. (ADIL), was involved in a transaction on March 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report also did not provide information on the number of shares held by Truluck after the transaction. Investors are advised to seek additional information to fully understand the impact of this event on their investment decisions.
Joseph Truluck, the Chief Financial Officer of Adial Pharmaceuticals, Inc. (ADIL), was involved in a transaction on March 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of the shares, transaction price, and the total value of shares, were not disclosed in the announcement. The report also did not provide information on the number of shares held by Truluck after the transaction. Investors are advised to seek additional information to fully understand the impact of this event on their investment decisions.
阿迪爾製藥公司（ADIL）首席財務官約瑟夫·特魯魯克於2024年3月25日參與了一筆交易。公告中未披露該交易的具體細節，包括行動類型、狀態、所涉股票數量、股票性質、交易價格和股票總價值。該報告也沒有提供有關Truluck在交易後持有的股票數量的信息。建議投資者尋求更多信息，以充分了解這一事件對其投資決策的影響。
阿迪爾製藥公司（ADIL）首席財務官約瑟夫·特魯魯克於2024年3月25日參與了一筆交易。公告中未披露該交易的具體細節，包括行動類型、狀態、所涉股票數量、股票性質、交易價格和股票總價值。該報告也沒有提供有關Truluck在交易後持有的股票數量的信息。建議投資者尋求更多信息，以充分了解這一事件對其投資決策的影響。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。